Search research articles
Contact Us
Filters
Showing results (51-60 of 136) with videos related to
Page
of 14
Sort By:
Blood
|
July 5, 2014
Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination
Wendy T Parker, Stuart R Phillis, David T O Yeung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy
Wendy T Parker, Rebecca M Lawrence, Musei Ho, et al.
Blood Cancer Journal
|
September 11, 2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Chung H Kok, Verity A Saunders, Phuong Dang, et al.
Leukemia
|
June 11, 2026
Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib
Chung Hoow Kok, Naranie Shanmuganathan, Verity A Saunders, et al.
Blood
|
June 10, 2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
Min Tang, Mithat Gonen, Alfonso Quintas-Cardama, et al.
Blood
|
April 20, 2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Susan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
The Journal of Clinical Investigation
|
August 22, 2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P Shah, Brian J Skaggs, Susan Branford, et al.
Cancer
|
July 4, 2007
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha
Susan Branford, Timothy Hughes, Alvin Milner, et al.
Leukemia & Lymphoma
|
June 9, 2020
Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 <i>BCR-ABL1</i> transcripts in chronic myeloid leukemia
Ilaria S Pagani, Phuong Dang, Verity A Saunders, et al.
Haematologica
|
August 2, 2013
What challenges remain in chronic myeloid leukemia research?
Angelo M Carella, Susan Branford, Michael Deininger, et al.
Page
of 14
Search research articles
Search
Showing results (51-60 of 136) with videos related to
Sort By:
Page
of 14
Blood
|
July 5, 2014
Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination
Wendy T Parker, Stuart R Phillis, David T O Yeung, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 13, 2011
Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy
Wendy T Parker, Rebecca M Lawrence, Musei Ho, et al.
Blood Cancer Journal
|
September 11, 2023
Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib
Chung H Kok, Verity A Saunders, Phuong Dang, et al.
Leukemia
|
June 11, 2026
Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib
Chung Hoow Kok, Naranie Shanmuganathan, Verity A Saunders, et al.
Blood
|
June 10, 2011
Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells
Min Tang, Mithat Gonen, Alfonso Quintas-Cardama, et al.
Blood
|
April 20, 2002
High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance
Susan Branford, Zbigniew Rudzki, Sonya Walsh, et al.
The Journal of Clinical Investigation
|
August 22, 2007
Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency
Neil P Shah, Brian J Skaggs, Susan Branford, et al.
Cancer
|
July 4, 2007
Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha
Susan Branford, Timothy Hughes, Alvin Milner, et al.
Leukemia & Lymphoma
|
June 9, 2020
Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 <i>BCR-ABL1</i> transcripts in chronic myeloid leukemia
Ilaria S Pagani, Phuong Dang, Verity A Saunders, et al.
Haematologica
|
August 2, 2013
What challenges remain in chronic myeloid leukemia research?
Angelo M Carella, Susan Branford, Michael Deininger, et al.
Page
of 14